Biocon: From Generics Manufacturing to Biopharmaceutical Innovation Case Solution

Founded in 1978 as a joint venture between Biocon Biochemicals Ltd., Ireland, a company run by Ms. Kiran Mazumdar-Shaw, a young Indian entrepreneur, Biocon has relied heavily on the income from the production of enzymes and generic drugs. However, competitive pressures within the country and in other developing economies like China was rapidly eroding price levels in these sectors. Moreover, the adoption of the TRIPS Agreement of the WTO in India in 2005 meant that based on the generic that many pharmaceutical and biotechnology companies in India had followed strategy may not be feasible. To continue on the current path of growth, Biocon need to consider moving to be a producer of biogenerics to become an innovative global biopharmaceutical company. Conscious strategy in an emerging industry, highlights the effects of the groups in the strategy and the effects of national and supranational factors on strategy. Leadership issues and low-cost strategies for diversification are also discussed.
by
Jeroen Van Den Berg,
Michael J. Enright,
Venkat Subramanian
Source: University of Hong Kong
48 pages.
Release: June 27, 2007. Prod #: HKU657-PDF-ENG
Biocon: Case manufacturing generic biopharmaceutical solutions innovation

Biocon: From Generics Manufacturing to Biopharmaceutical Innovation Case Solution
Share This